Focus: Protara Therapeutics is a publicly traded biotech company focused on cell therapy and gene therapy for rare and specialized indications. The company operates with a lean footprint as a clinical-stage developer with no marketed products.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
Growing — net +5 jobs in 30d
8 jobs added vs 3 removed. Steady team buildout.
Protara is a pre-revenue biotech with adequate funding but stalled hiring and widening losses, suitable only for highly risk-tolerant candidates seeking deep technical immersion in cell therapy without near-term career momentum.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Protara Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Protara Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Protara Therapeutics (TARA) seeks more shares, officer protections in 2026 vote - Stock Titan
Protara Therapeutics (TARA) seeks more shares, officer protections in 2026 vote Stock Titan
BlackRock (TARA) reports 3,387,459 shares, 6.3% stake (Schedule 13G) - Stock Titan
BlackRock (TARA) reports 3,387,459 shares, 6.3% stake (Schedule 13G) Stock Titan
Bladder cancer trial update from 31 patients goes to urology meeting - Stock Titan
Bladder cancer trial update from 31 patients goes to urology meeting Stock Titan
Protara Therapeutics to Present Updated, Interim 12-Month - GlobeNewswire
Protara Therapeutics to Present Updated, Interim 12-Month GlobeNewswire
Baker Brothers reports multiple common-stock sales (NASDAQ: TARA) - Stock Titan
Baker Brothers reports multiple common-stock sales (NASDAQ: TARA) Stock Titan
TARA (NASDAQ: TARA) files Form 144 listing multiple proposed share sales - Stock Titan
TARA (NASDAQ: TARA) files Form 144 listing multiple proposed share sales Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles